<DOC>
	<DOCNO>NCT02369965</DOCNO>
	<brief_summary>The purpose study determine efficacy safety albuvirtide plus lopinavir-ritonavir HIV-1-infected adult fail first-line antiretroviral therapy .</brief_summary>
	<brief_title>Test Albuvirtide Experienced Patients</brief_title>
	<detailed_description>This 48-week , randomize , control , open-label , multicenter study safety efficacy albuvirtide plus lopinavir-ritonavir HIV-1 infect adult fail first antiretroviral regimen HIV-1 RNA level &gt; = 1000 copies/mL screen . Subjects meet inclusion criterion randomize 1:1 ratio receive either albuvirtide + lopinavir-ritonavir lopinavir-ritonavir + TDF + 3TC . If TDF use current regimen genotypic resistance test show primary mutation TDF , zidovudine ( AZT ) abacavir use . Albuvirtide give weekly intravenous infusion LPV/r give twice daily . The primary end point percentage participant HIV-1 RNA &lt; 50 copies/mL Week 48 , secondary end point include change HIV-1 RNA baseline Week 48 , percentage participant HIV-1 RNA &lt; 400 copies/mL Week 48 , change CD4 count baseline Week 48 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1 . Male female patient age 16 60 year old ; 2 . Previously document HIV infection standard antibodybased test ; 3 . Previous antiretroviral therapy ( ART ) NRTIs/NNRTIs 6 month ; 4 . HIV RNA≥1000 copies/ml ; 5 . In healthy condition physical examination , biochemistry , hematology urinalysis test , electrocardiogram etc. , without serious liver renal damage ; 6 . Fully understand purpose , characteristic , procedure trial , potentially adverse event might occur study ; willing able sign inform consent . 1 . Patients acute HIV infection , AIDSrelated disease , severe opportunistic infection tumor ; 2 . Previously receive protease inhibitor , HIV fusion inhibitor , HIV vaccine , receive investigational drug within 3 month ; 3 . Cotreatment hepatitis virus ; 4 . Having abnormal value screen follow : Hemoglobin &lt; 9g/dL , White blood count &lt; 2×10^9/L , Neutrophil &lt; 1×10^9/L , Platelet count &lt; 75×10^9/L , Aminopherase &gt; 3fold upper limit normal value , Total bilirubin &gt; 2fold upper limit normal value , Creatinine &gt; upper limit normal value , Creatine phosphokinase &gt; 2fold upper limit normal value ; 5 . With allergic constitution , allergic history investigational drug ART drug ; 6 . With serious chronic disease , metabolic disease ( diabetes ) , mental disorder nervous disease ; 7 . Had history hemophilia A B ; 8 . Alcohol abuse drug abuse ; 9 . Pregnant woman , breast feeding woman , woman childbearing age disagreed use birth control ; 10 . Unsuitable participate study opinion site investigator .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>AIDS</keyword>
	<keyword>Albuvirtide</keyword>
	<keyword>Treatment-experienced</keyword>
	<keyword>Fusion inhibitor</keyword>
</DOC>